The core therapeutic use of this medicine is aligned with managing symptoms of acute (short-lived) moderate pain in situations where simpler options have not been adequate.

This combination analgesic is considered relevant in contexts marked by increased discomfort where short-term symptom management is appropriate. It is applied across domains where additional symptomatic support is needed, assisting in managing pronounced, acute episodes such as headaches, musculoskeletal discomfort, and dental pain. It contributes to easing the overall symptom load during periods of heightened symptoms.

The medication may assist with symptom clusters that create noticeable functional strain, specifically when pain is associated with inflammatory or irritative states or when patients experience symptoms related to systemic imbalance (fever). It is relevant for easing symptomatic manifestations, contributing to improved comfort during periods of heightened symptoms.

“It is relevant in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is needed.”

This product is relevant in contexts involving acute or disruptive episodes, often used during phases when symptoms become more noticeable following events like dental intervention or post-traumatic recovery. It is commonly used when short-term symptomatic assistance is needed, assisting with maintaining functional stability by providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Pain and Fever	Description
Primary Domain	Applied across domains where additional symptomatic support is needed for pain intensity that is mild to moderately severe.
Secondary Benefits	Assists with managing symptoms related to inflammatory or irritative states and elevated body temperature.
Use Context	Applied for short-term symptomatic assistance in conditions involving recurrent or episodic manifestations.

Regulatory References

1. European Medicines Agency guidance on codeine-containing medicines

Dolviran N is a combination pain reliever containing Acetylsalicylic acid (Aspirin), Codeine, and Caffeine. Like all medications, it is not suitable for everyone.

Who Should NOT Use Dolviran N (Contraindications)

Do not use this medicine if you have:

• A known allergy or hypersensitivity to Aspirin, other salicylates, Codeine (or other opioids), or any other component of the tablet.
• A history of asthma attacks, hives (urticaria), or allergic reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
• An active peptic ulcer, erosive gastritis, or a history of recurrent gastrointestinal bleeding.
• Severe liver or kidney insufficiency.
• A hemorrhagic diathesis (bleeding tendency) or are concurrently taking anticoagulants (blood thinners).
• Severe respiratory depression or diminished respiratory reserve (e.g., emphysema), due to the Codeine content.
• Intracranial lesions or other conditions where increased intracranial pressure may be a risk.
• Are under 12 years of age.

Use with Caution

Consult your healthcare professional before use if you have impaired renal function, G6PD deficiency, or cardiovascular diseases. Caution is also advised in the elderly due to an increased risk of side effects. Use during pregnancy and breastfeeding is generally not recommended due to potential risks to the fetus or infant, and should only be considered under strict medical guidance.

Dolviran N Interactions with other medicines and products

Dolviran N is a combination analgesic that contains paracetamol (acetaminophen), propyphenazone, and caffeine. The potential for drug interactions is primarily related to the individual active components. It is essential to inform your healthcare provider about all medicines, over-the-counter products, and supplements you are taking to manage potential risks.

Interactions Involving Paracetamol (Acetaminophen)

• Anticoagulants: Concomitant use with oral anticoagulants, such as warfarin, may enhance the anticoagulant effect, increasing the risk of bleeding. Regular monitoring of clotting parameters is advised.
• Enzyme Inducers: Medicines that induce liver enzymes, including certain antiepileptics (e.g., phenobarbital, phenytoin, carbamazepine) and rifampicin, may increase the formation of toxic paracetamol metabolites, raising the risk of liver damage.

Interactions Involving Propyphenazone

Propyphenazone, a pyrazolone derivative, may interact with medicines in a manner similar to other non-steroidal anti-inflammatory drugs (NSAIDs).

• Blood Cell Depression: Co-administration with drugs known to cause bone marrow suppression or leukopenia should be monitored closely.

Interactions Involving Caffeine

Caffeine can influence the effects of various substances:

• CNS Stimulants: Combining Dolviran N with other caffeine-containing products (e.g., coffee, tea, energy drinks) or other central nervous system stimulants can lead to excessive stimulation, nervousness, or palpitations.
• Other Interactions: Caffeine may interfere with the metabolism of certain medicines like theophylline and ciprofloxacin.

General Advice

• Alcohol: Avoid alcohol consumption. Alcohol increases the hepatotoxicity (liver toxicity) risk associated with paracetamol and propyphenazone, even at therapeutic doses.
• Other Pain Relievers: Do not use Dolviran N with other medicines containing paracetamol, propyphenazone, or other NSAIDs to prevent potential overdose and additive side effects.

How Dolviran N Works: The Mechanism of Action

The mechanism involves complementary action on nociceptive signal generation and central processing pathways.

Dual Modulation of Nociceptive Pathways

The combined pharmacodynamics modulate nociceptive signal transmission pathways. The mechanism acts simultaneously to inhibit the synthesis of chemical mediators involved in nociceptor sensitization in the body's periphery, while also modifying the transmission and interpretation of afferent signals within the spinal cord and brain via receptor agonism. This strategy is applied to regulate two key mechanistic domains that modulate pathways associated with increased signal activity.

Core Mechanistic Actions

The central action engages specific mu-opioid receptors (mu-OR) within the Central Nervous System (CNS) by utilizing Codeine's active metabolite (Morphine) as a full agonist. Activation of the mu-OR alters the signaling dynamics of pain-transmitting neurons, leading to a suppression of afferent signal processing.

The peripheral action involves Acetylsalicylic Acid's action as an irreversible inhibitor of the Cyclooxygenase (COX) enzyme system. This molecular blockade prevents the synthesis of inflammatory mediators, such as prostaglandins, at the tissue level. The result is a dampening of the chemical sensitization of peripheral nerve endings, which ultimately results in the reduction of inflammatory mediator concentrations at the tissue level.

Constraint by Metabolic Activation

The full intended physiological activity of the central mechanism is structurally dependent on the body's metabolic conversion of Codeine to Morphine via the CYP2D6 enzyme. Genetic variations in this enzyme can lead to significantly reduced levels of the active agonist, functionally constraining the central physiological activity in certain individuals.

Dolviran N is strictly intended for oral administration as a solid unit dose, typically provided as a tablet or capsule. The standard adult regimen involves taking one or two units per dose, administered every four to six hours as needed for acute symptoms, with a strict minimum interval of four hours required between administrations.

Usage is structured by specific limits. The total intake of the combination analgesic must not exceed eight units over a 24-hour period. Furthermore, the medicine is reserved for short-term management and should not be used for more than three consecutive days for pain relief.

The unit dose should be swallowed whole with water. To mitigate the potential for irritation from the Acetylsalicylic Acid component, the medicine is often administered with food or milk.

Specific usage restrictions apply to certain populations. The medicine is generally contraindicated in children younger than 12 years and is subject to special limitations in adolescents. A lower starting dose may be necessary for older adults or individuals with documented renal or hepatic impairment due to altered drug clearance.

Research Evidence: Overview of Studies for Dolviran N

Evidence for Use in Acute Postoperative Pain

The combination of Acetylsalicylic Acid (ASA) and Codeine was evaluated in research exploring contexts of short-lived pain following procedures, such as minor oral surgery or dental extractions. Randomized Controlled Trials (RCTs) were the main study types applied in research exploring how symptoms change over time, often focusing on a single-dose administration. Research examined outcomes related to physical discomfort, such as changes in pain intensity over defined time intervals.

Findings describe patterns observed in the studies over the first few hours after taking a single dose. Evidence is limited specifically for the pairing of ASA and Codeine compared to other combinations. Follow-up durations were limited to the immediate post-dose period, meaning long-term outcomes are not well characterized or observed patterns during multi-day use.

Evidence for Use in General Moderate Acute Pain

This combination product was evaluated in research exploring general acute pain conditions characterized by fluctuating or episodic manifestations. These studies focused on episodes where symptoms become more noticeable, monitoring outcomes related to patient-reported outcomes describing perceived discomfort. Research highlights changes measured during the study period, with findings that varied across different studies. The evidence contributes to the broader evidence landscape but often involved combining data from trials using Codeine with non-ASA analgesics, which introduces uncertainty regarding the specific contribution of the ASA component in this context. Evidence quality varies across studies for this broad indication, and certainty remains low.

Overview of Long-Term Studies and Follow-Up

The existing body of research for the ASA and Codeine combination product mainly consists of short-term clinical trials that studied outcomes related to acute pain or fever. The evidence focuses predominantly on single-dose findings. As a result, long-term outcomes are not fully established and there is limited information for how symptoms evolve with extended use.

What is Still Uncertain About Dolviran N Research

While research has explored the combination in the context of episodic symptom patterns, several aspects remain uncertain or unstudied:

• Comparative evidence is lacking for the specific ASA and Codeine pairing against all possible first-line non-opioid options in many common acute pain scenarios.
• Evidence quality varies across studies, and findings were mixed for the general moderate acute pain indication.
• Follow-up durations were limited across almost all acute pain trials.

This research provides context but not individual predictions; findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Codeine for Acute Dental Pain and Acute Pain Related to Dental Procedures: A Review of Clinical Effectiveness - NCBI (Systematic Review)
2. Safety and efficacy of the combination Acetaminophen-Codeine in the treatment of pain of different origin (Systematic Review/Meta-analysis)
3. WHO Model List of Essential Medicines (Inclusion of Codeine and ASA for pain management)

Common questions about Dolviran N (FAQ)

---

Q: How quickly should I expect to feel a difference after taking Dolviran N?

Official regulatory data for analgesics in this class generally indicate that the onset of action typically begins within 30 to 60 minutes after taking a dose. This range indicates when the onset of pain relief is typically observed.

---

Q: Is Dolviran N a painkiller, an anti-inflammatory, or something else entirely?

Dolviran N is primarily classified as an analgesic (a painkiller) and an antipyretic (a fever reducer). It also contains a component (propyphenazone) that has demonstrated anti-inflammatory properties.

---

Q: What happens if I accidentally miss a dose of Dolviran N?

Official instructions describe that if a dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled time. If that is the case, the missed dose should be skipped, and the regular schedule resumed. Double doses must not be taken to compensate for a missed one.

---

Q: Is it normal to feel a mild headache when first starting Dolviran N?

Headaches and dizziness are sometimes reported as less common or rare adverse reactions for the components within this combination medicine. If a persistent or severe headache occurs, professional medical consultation is necessary.

---

Q: Can people with a history of stomach issues take Dolviran N?

Due to the NSAID-like component (propyphenazone), this medicine is generally not recommended or may even be contraindicated for individuals with a history of severe stomach conditions. This typically applies to individuals with conditions such as active or historical gastric ulcers or gastrointestinal bleeding problems.

---

Q: Does Dolviran N affect blood pressure or heart rate?

The caffeine component in this medicine is a stimulant and can potentially cause side effects like nervousness or palpitations (changes in heart rate) in some users. Official warnings often include caution for individuals with pre-existing cardiovascular conditions.

---

Q: Does Dolviran N interfere with birth control pills?

Regulatory guidance suggests that caffeine, one of the components, can potentially interfere with the metabolism of certain oral contraceptives. It is necessary to inform a healthcare provider about all medicines taken, including contraceptives, to manage potential risks.

---

Q: How does my body break down and get rid of Dolviran N?

The active components of this medicine are primarily metabolized (broken down) in the liver and then excreted from the body through the urine. The full effect of the codeine component depends on a specific liver enzyme (CYP2D6) to convert it to its active form.

---

Q: Can people develop tolerance to Dolviran N over time?

Official warnings for the opioid component (codeine) state that both tolerance (needing higher doses for the same effect) and physical dependence can develop with repeated use. This is why the medicine is only intended for short-term use.

---

Q: What is the shelf life of Dolviran N tablets?

The shelf life or expiration date is explicitly printed on the original product packaging, as required by regulatory standards. The medicine must only be used before this marked date and should be properly disposed of afterward.

---

Q: Are there specific symptoms that Dolviran N is best at treating?

Official indications show the medicine is used for acute mild to moderate pain across various situations. The medicine has been studied in managing symptoms related to headache, toothache, and short-term post-operative pain.

---

Q: Why might a doctor switch a patient from a different drug to Dolviran N?

A doctor may choose this combination because it offers a dual-action approach to pain relief. This is beneficial when a patient's pain is not adequately controlled by a single analgesic alone. The combination acts on both central and peripheral pain pathways.

---

Q: What kind of relief should I expect from Dolviran N?

Regulatory data indicates the medicine is intended to provide effective relief from acute mild to moderate pain. Official information indicates the combination is designed to offer a dual approach that may result in quicker and more effective pain relief compared to single agents.

---

Q: Are there specific genetic factors that affect how Dolviran N works?

Yes, genetic factors play a role in how the codeine component works. Its effectiveness relies on the CYP2D6 enzyme in the liver for conversion to morphine. Genetic variations in this enzyme can lead to significantly reduced analgesic effectiveness in some individuals.

---

Q: Does Dolviran N have any mood-altering effects?

As an opioid, the codeine component affects the central nervous system. Common effects include drowsiness and dizziness, but the medicine can also cause mood-altering effects such as euphoria or confusion.

---

Q: What should I keep in mind when traveling with Dolviran N?

Because this medicine contains codeine, an opioid, it is legally regulated as a controlled substance in many places. Official guidance related to controlled substances suggests that documentation, such as a prescription or doctor's note, may be necessary when traveling, particularly across international borders.

---

Q: Will Dolviran N show up on a standard drug screening test?

Yes. Due to the presence of codeine, an opioid, the medicine can cause a positive result on certain drug screening tests that look for opioids or related substances.

---

Q: Can Dolviran N cause or contribute to problems sleeping?

The caffeine component acts as a central nervous system stimulant and can potentially lead to problems like insomnia (difficulty falling or staying asleep) or general restlessness in some individuals.

---

Q: Is it common for people to switch off of Dolviran N after a short time?

Yes, this is the intended use. Official usage dictates the medicine is strictly for short-term management and should not be used for pain relief for more than three consecutive days.

---

Q: What is the average duration of treatment with Dolviran N?

Official recommendations are for short-term use only. The maximum duration for pain relief is generally restricted to three consecutive days. Any prescribed treatment should be for the shortest possible duration.

---

Q: Do I need a prescription to get Dolviran N?

Yes. Due to the presence of codeine, an opioid, this medicine is typically classified as a prescription-only medicine (POM) in most jurisdictions, meaning it requires a valid prescription from a licensed practitioner.

---

Q: Does the efficacy of Dolviran N change depending on a person's weight?

While standard adult dosing is generally used, official guidance notes that the process of drug clearance can be altered in individuals with renal or hepatic impairment. Dosing may need to be adjusted for these special populations, regardless of their weight.

How to Store and Dispose of Dolviran N

Official regulatory documents require that Dolviran N (Acetylsalicylic Acid/Codeine) must be kept out of the sight and reach of children to prevent accidental ingestion, given the opioid component.

Requirement	Official Storage Constraints
Temperature	Store at controlled room temperature (e.g., 15 C to 30 C / 59 F to 86 F). Do not refrigerate or freeze [2.1].
Protection	Store in the original container, tightly closed, and protected from excess heat and moisture. Dispense in a tight, light-resistant container [2.1, 2.2].

Disposal Instructions:

Unused or expired Dolviran N must be disposed of safely. The preferred method is through a drug take-back program or a DEA-authorized collector to prevent drug diversion [3.3, 4.1]. If no take-back option is available, the drug should be removed from its container, mixed with an undesirable substance (like coffee grounds), placed in a sealed bag, and then thrown into the household trash [3.3]. The medicine must not be flushed down a toilet or sink [3.2].